Skip to main content welcomes BeiGene to Basel

| News welcomes BeiGene to Basel


BeiGene, Ltd., a global commercial-stage biopharmaceutical company, has established a regional headquarters in Basel. assisted BeiGene in evaluating and establishing the new site.

BeiGene in Basel

The Nasdaq and Hong Kong Stock Exchange-listed company is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

From its new location in Basel, BeiGene will manage its European clinical trial operations and prepare for the potential launch of its drug candidates outside of Asia. The new presence marks another milestone for BeiGene on its way to becoming a leading global bio-pharma company.

Access to a large and highly skilled talent pool, a business-friendly environment and close proximity to the European market were key drivers of BeiGene’s decision to establish operations in Basel. Basel is home to several of the world’s leading oncology companies and a vibrant biotech hub. Many global life sciences companies manage their commercial activities from Basel.

BeiGene has a global team of over 1,300 employees, including more than 500 people in its clinical team in China, the United States and Australia. The company has offices in China in Beijing, Guangzhou, Shanghai and Suzhou; in the United States in Cambridge, MA, Ridgefield Park, NJ, and Emeryville and San Mateo, CA; and in Europe in Basel, Switzerland.

Share this article

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.